Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection.

• Published in: Clinical Microbiology and Infection
• Main Authors: Einarsdottir, H M, Erlendsdottir, H, Kristinsson, K G, Gottfredsson, M
• Format: Article in Journal/Newspaper
• Language: English
• Published: Blackwell Science 2005
• Subjects: Aged; Child; Preschool; HIV Infections; Immunologic Deficiency Syndromes; Multiple Myeloma; Pneumococcal Infections; Prevalence; Recurrence; Risk Factors; Streptococcus pneumoniae; Retrospective Studies; Iceland
• Online Access: http://hdl.handle.net/2336/2860; https://doi.org/10.1111/j.1469-0691.2005.01221.x

To access publisher full text version of this article. Please click on the hyperlink in Additional Link field Recurrent invasive infections caused by Streptococcus pneumoniae are rare, and often considered to be indicative of serious underlying illness. However, the prevalence of this problem, and the relevance of specific predisposing conditions, can be hard to assess, since many of the studies are based on specific risk groups. A population-based study of recurrent invasive pneumococcal disease in Iceland during the 30-year period 1975-2004 was performed. Clinical information, including mortality and vaccine use, was analysed retrospectively. Invasive pneumococcal isolates were serotyped and susceptibility testing was performed. During this period, 36 (4.4%) of 819 patients who survived an initial infection experienced recurrence, with a median time between episodes of 9.7 months. Pneumonia with bacteraemia was the most common clinical diagnosis (48% of cases), followed by bacteraemia without a clear focus (21%) and meningitis (13%). Most (94%) of the patients had identifiable predisposing conditions, most commonly, multiple myeloma in adults, and antibody deficiencies in children. Compared with children, adults were more likely to present with pneumonia (65% vs. 18%; p 0.0001). No significant change in the 30-day mortality rate was observed during the three decades of the study. Only 26% of eligible patients received pneumococcal vaccination. Patients with recurrent invasive pneumococcal disease should be investigated thoroughly for underlying diseases. Greater use of pneumococcal vaccines should be encouraged among high-risk patients. More effective preventive and therapeutic measures are needed to improve outcomes.